11/04/2011 Savara Inc. Joins SAFE-BioPharma Association

FT. LEE, N.J. (November 04, 2011) – Savara Pharmaceuticals (http://www.savarapharma.com), an inhalation drug development company targeting niche therapeutic areas, has joined SAFE-BioPharma Association. SAFE-BioPharma manages the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

Savara, which focuses on improving existing small molecule medicines through advanced formulation and delivery technologies across a number of therapeutic areas including asthma, cystic fibrosis and lung cancer, is incorporating the SAFE-BioPharma standard to improve its overall operating efficiencies.

“We are about to enter clinical trials and wanted a tool to help us eliminate paper from our systems, save time and become more efficient. For us, SAFE-BioPharma is the logical choice,” said Chris Marich, vice president, business operations, Savara.

8/15/2011 Savara Receives Grant Award from National Institute of Allergy and Infectious Diseases

Proceeds used to progress Pediatric Asthma Therapeutic to IND

Austin, TX, Aug. 15, 2011 -- Savara Inc., an inhalation product development company, was recently awarded a Phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID).

After NIAID and independent review, reviewers concluded that Savara’s proposed therapeutic addresses an important clinical need in pediatric asthma. With innovative foundational technology, a clear clinical path and a team with a proven track record of product development, NIAID selected to fund Savara from a large pool of applicants. This provides additional validation of the program’s clinical potential and progress to date.